The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

China slaps Pfizer with $500,000 in Viagra penalties for pharmacy tie-up

Pfizer has no problem keeping sales for Viagra flying high in China, where brand awareness campaigns and changing attitudes toward sex have given it a sizable hold on the ED market. But the company is facing some headwind in the country, as Chinese marketing authorities slapped Pfizer with a fine for paying local drugstores to promote its blockbuster ED med.

Pfizer plots Ibrance expansion as early-stage breast cancer trial begins

Pfizer's new breast-cancer-fighter, Ibrance, has gotten off to a quick start in patients with advanced breast cancer. And now, the company is embarking on a study to see whether it can work earlier in the disease, too.

Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials

Pfizer's meningitis B vaccine Trumenba won the FDA's blessing nearly a year ago based on impressive midstage results and a national unease about the infection spreading on college campuses. Now, just in time for the back to school season, the New York-based pharma on Friday announced positive late-stage results in nearly 7,000 individuals that confirmed the vaccine's effectiveness against certain meningits B strains.

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers--including Evercore ISI analyst Umer Raffat, who polled investors last week. And while there are lots of possibilities floating around, his respondents seem to have a pair of potential deals in mind.

Analyst: Pfizer may favor Hospira's Remsima over in-house Remicade biosim

When Pfizer agreed to shell out $15 billion-plus for Hospira earlier this year, the pharma giant added major heft to its biosimilars pipeline. At the time, CEO Ian Read said the two companies had "complementary" portfolios of biosimilar prospects--and his tune hasn't changed since.

Pfizer to cover NHS docs' script-switching costs in latest Lyrica-protecting move

Pfizer plans to pay doctors in England to prescribe its drug Lyrica. But don't jump to conclusions. These payments are in a category all their own.

Pfizer takes the lead in another hot immuno-oncology contest

The immuno-oncology arena is seeing a new player enter the hottest game in R&D. And some of the biggest companies in biopharma are pushing into early-stage studies, spawning a fresh rivalry as researchers jockey for the lead position in what promises to be a hotly contested race.

British watchdog cracks down on Pfizer for huge price hikes on epilepsy drug

Last year, U.K. officials lambasted Pfizer's proposed takeover of AstraZeneca, and Pfizer has drawn criticism for its hard line on generic Lyrica use. Now, Britain's competition watchdog is accusing the drugmaker of violating U.K. and European laws by jacking up costs for another epilepsy med.

With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&A

Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics, not to mention a solid biosimilars pipeline.

Pfizer nabs rights to Copaxone copycats, setting up head-to-head generics fight with Novartis

So far, the market looks ripe for copies of Teva's multiple sclerosis hit, Copaxone. And Pfizer wants to get in on that.